ArticleGynecologic oncology reports2026
Immunotherapy induced sarcoidosis in a 47-year-old female with stage IIIC cervical cancer on pembrolizumab: A case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As immune-checkpoint inhibitors (ICIs) use increases in gynecologic oncology, it is imperative to remain alert for immune-related adverse events (irAEs). Although ICI-induced sarcoidosis is a rare irAE, it can closely mimic metastatic progression on radiographic imaging and requires prompt recognition and treatment to minimize interruptions to immunotherapy treatment. Case: A 47-year-old with stage IIIC cervical cancer on maintenance pembrolizumab experienced multiple immune-related adverse events which interfered with consistent treatment. Immunotherapy induced sarcoidosis was eventually diagnosed with tissue biopsy after multiple imaging studies failed to differentiate between osseous metastases versus inflammation. She is undergoing current treatment with steroid and methotrexate treatment and temporary discontinuation of immunotherapy. Conclusion: This is the first reported cases of ICI-induced sarcoidosis in a patient with cervical cancer. Given the radiographic similarities between metastases and sarcoidosis, continued surveillance throughout ICI therapy is essentiall, especially given that the incidence of irAEs will likely rise with increased ICI use in gynecologic oncology. This case also demonstrates the importance of multidisciplinary collaboration in managing ICI-related toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.